Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 12/12/2025			5-day change	1st Jan Change
186,800.00 ^KRW	+0.05%		+1.91%	+3.61%

12-11	Celltrion USA, Inc. announced that it expects to receive $532.1 million in funding from Celltrion, Inc.	CI
12-10	Celltrion, Inc. announces Annual dividend	CI

Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on November 21, 2024.

Published on 12/18/2024 at 07:00 am GMT

S&P Capital IQ

Celltrion, Inc.

+0.05%

From November 21, 2024 to December 16, 2024, the company has repurchased 583,431 shares, representing 0.28% for KRW 106,737.43 million. With this, the company has completed the repurchase of 583,431 shares, representing 0.28% for KRW 106,737.43 million under the buyback announced on November 21, 2024.

Latest news about Celltrion, Inc.

12-11	Celltrion USA, Inc. announced that it expects to receive $532.1 million in funding from Celltrion, Inc.	CI
12-10	Celltrion, Inc. announces Annual dividend	CI
12-03	Celltrion Announces U.S. FDA Approval of 300mg strength of OMLYCLO®?	CI
11-28	Celltrion, Inc. Receives Health Canada Approval for Eydenzelt®?, a Biosimilar Confirming Eylea®? (aflibercept 2Mg)	CI
11-26	Celltrion Announces Publication of Post-Hoc Analysis of Liberty-Cd Study of Zymfentra®? (Infliximab-Dyyb)	CI
11-19	Celltrion to invest up to $478 million to expand US factory in response to tariffs	RE
11-18	Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo?? 300Mg	CI
11-18	Celltrion, Inc Announces European Commission Grants Approval of Remsima?? IV Liquid Formulation, World's First Liquid Formulation of IV Infliximab	CI
11-14	Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-07	Prime Medicine Q3 net loss narrows	RE
10-30	U.S. FDA Grants Interchangeability Designations to Celltrion's Denosumab Biosimilar, STOBOCLO (denosumab-bmwo) and OSENVELT (denosumab-bmwo)	CI
10-22	Celltrion to sell 746 million won worth of own shares	RE
10-21	Celltrion's Q3 Operating Income, Sales Rise	MT
10-20	Wellscare Signs A Memorandum of Understanding with Celltrion Canada	CI
10-17	Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on September 17, 2025.	CI
10-17	FDA Approves Expanded Pediatric Indications for YUFLYMA®? (Adalimumab-Aaty) and Unbranded Adalimumab-AatY in the United States	CI
10-14	Celltrion, Inc.'s Equity Buyback announced on September 17, 2025, has closed with 572,932 shares, representing 0.26% for KRW 100,000.03 million.	CI
10-10	Samsung, SK Hynix Gains Push South Korean Stocks Higher; Samsung Biologics Adds 1% on ExellenS Launch	MT
10-10	Celltrion Receives U.S. FDA Approval for EYDENZELT®? (aflibercept-boav), Biosimilar Confirming EYLEA®? (aflibercept)	CI
10-10	US FDA Approves Celltrion's EYLEA Biosimilar for Multiple Retinal Diseases	MT
10-06	Celltrion, Inc. Presents Positive Real-World Data on Switching from Intravenous (Iv) to Subcutaneous (Sc) Injectioniximab At Ueg Week 2025 Meet the Expert Sessions	CI
10-06	Hikma, Celltrion Sign Exclusive License Deals for Six Biosimilars in MENA Region	MT
10-06	Hikma & Celltrion strengthen partnership to expand biosimilar access in MENA	RE
10-02	Celltrion, Inc. Launches AVTOZMA®? (Tocilizumab-anoh) Intravenous (IV) Formulation in the United States	CI
09-26	South Korean shares snap 4-week rally on US tariff woes; won drops	RE

Chart Celltrion, Inc.

Duration

Period

A068270: Dynamic Chart

Company Profile

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Employees

2,680

Sector

Biotechnology & Medical Research

Calendar

03-03 - Q4 2025 Earnings Release (Projected)

More about the company